Harbor is now

7 Mounjaro & Zepbound Alternatives, Including Compounded Tirzepatide Shots

Seven options when Mounjaro or Zepbound is out of reach, led by compounded tirzepatide, which is not FDA approved, then Zepbound vials, Wegovy, Foundayo and three more. What each is and how a clinician chooses.

Clinically reviewed
Medically reviewed by Harbor Health TeamMedical Content Team11 min read

The top three

Weekly injections, tirzepatide first
Our pick

01  Compounded tirzepatide

Staying on tirzepatide at one flat monthly price

02  Zepbound vials

Brand tirzepatide without the pen

Weeklybrand injection

03  Wegovy

A weekly brand GLP-1 when your plan covers it

Weeklybrand injection

Then four more. Wegovy is the weekly brand semaglutide shot, Foundayo and the Wegovy pill are daily tablets, and Saxenda is a daily injection that now has a generic.

Mounjaro alternatives at a glance

Mounjaro and Zepbound are one drug, tirzepatide, sold by Eli Lilly under two labels. Mounjaro is approved for type 2 diabetes in adults and in children 10 and older, while Zepbound is approved for long-term weight management in adults with obesity, or with overweight and a weight-related condition. Drugs@FDA lists no approved generic of either one.

Mounjaro alternatives come in three kinds: tirzepatide in another form, a different GLP-1 drug, or a pill. Seven are below, and every one needs a prescription. Harbor's compounded tirzepatide and semaglutide, which are not FDA approved, are two of them: one weekly injection at home, medication, clinician care and check-ins in one flat price, and a licensed clinician who decides whether treatment fits.

OptionActive drugFDA status for weightHow it is taken
Mounjaro (reference)TirzepatideNot labeled for weight (type 2 diabetes)Injection, once a week
Zepbound pen (reference)TirzepatideApproved, adultsInjection, once a week
Compounded tirzepatideTirzepatideNot FDA approvedInjection, once a week
Zepbound vialsTirzepatideApproved, adultsVial and syringe, once a week
WegovySemaglutideApproved, ages 12 and upInjection, once a week
Compounded semaglutideSemaglutideNot FDA approvedInjection, once a week
FoundayoOrforglipronApproved, adultsTablet once a day, with or without food
The Wegovy pillSemaglutideApproved, adultsTablet each morning, empty stomach
SaxendaLiraglutideApproved, ages 12 and upInjection, once a day

Approval status and schedules from each current FDA label on DailyMed, read November 19, 2026. Compounded drugs are not FDA approved and carry no FDA label.

Mounjaro alternatives for weight loss

These Mounjaro alternatives for weight loss start with compounded tirzepatide, which is not FDA approved, and Zepbound vials, which keep brand tirzepatide in a different format. Next come Wegovy and compounded semaglutide, the second of which is also not FDA approved, then two daily pills, Foundayo and the Wegovy pill, and Saxenda. The list doubles as Zepbound alternatives, since Zepbound is the weight label of the same drug.

Trial figures in the brand entries come from separate trials of brand drugs, each with its own length and population, so read them as context and not as a ranking. None of those label trials tested a compounded drug. For the drug being replaced, see MedlinePlus tirzepatide injection facts.

01

Compounded tirzepatide

Weekly GIP and GLP-1 injection, not FDA approved

$119$119

Compounded tirzepatide keeps the active ingredient of Mounjaro and Zepbound on the same once-weekly schedule, at a cash price that does not depend on insurance. It is a compounded drug, not FDA approved and not the same product as either brand, and the SURMOUNT and SURPASS trials tested the brand drugs only.

Where it wins

  • Tirzepatide once a week, the schedule the brand pens use
  • One flat monthly price as the dose goes up
  • No insurance required, and HSA or FSA cards are accepted
  • A clinician-guided taper and registered-dietitian aftercare at the end

What it costs you

  • Not FDA approved, so FDA has not reviewed it for safety, effectiveness or quality
  • Ruled out by a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2
  • A weekly injection, so not the choice for anyone set on a pill

Staying on tirzepatide at one flat monthly price

02

Zepbound vials

Brand tirzepatide in a vial, FDA approved

Weeklybrand injection

Zepbound vials hold the same brand tirzepatide as the Zepbound pen, drawn into a syringe once a week. Zepbound has been FDA approved since November 8, 2023, for long-term weight management in adults with obesity, or with overweight and at least one weight-related condition.

Where it wins

  • FDA approved, with the brand label trials behind it
  • Single-dose vials, plus a multi-dose vial that holds four doses
  • Also labeled for moderate to severe obstructive sleep apnea in adults with obesity

What it costs you

  • The self-pay route needs a prescription for a labeled use
  • Labeled for adults only
  • Not for anyone with a personal or family history of MTC or MEN 2

Brand tirzepatide without the pen

03

Wegovy

Semaglutide injection, FDA approved 2021

Weeklybrand injection

Wegovy is brand semaglutide, a GLP-1 receptor agonist injected once a week and FDA approved on June 4, 2021. Its label covers long-term weight management in adults and children 12 and older with obesity, and adults with overweight plus a condition tied to weight.

Where it wins

  • A different drug from tirzepatide, acting on GLP-1 alone
  • Also labeled to lower major cardiovascular risk in adults with heart disease
  • Label covers ages 12 and up

What it costs you

  • Brand coverage depends on your insurance plan
  • A change of drug, so your clinician sets a new starting dose
  • Not for anyone with a personal or family history of MTC or MEN 2

A weekly brand GLP-1 when your plan covers it

04

Compounded semaglutide

Weekly GLP-1 injection, not FDA approved

$89$89

Compounded semaglutide suits a reader whose clinician recommends a GLP-1-only option, the drug in Wegovy, in a weekly injection at a cash price that does not depend on insurance. It is a compounded drug, not FDA approved and not the same product as Wegovy.

Where it wins

  • Semaglutide once a week, the schedule Wegovy uses
  • One flat monthly price as the dose goes up
  • Built for gradual, consistent progress

What it costs you

  • Not FDA approved, and not reviewed by FDA before it is marketed
  • A change of drug from tirzepatide, so your clinician sets the dose
  • Not for anyone with a personal or family history of MTC or MEN 2

A weekly GLP-1-only option at one flat price

05

Foundayo

Orforglipron tablet, FDA approved 2026

Dailybrand tablet

Foundayo (orforglipron) is a once-daily GLP-1 pill that FDA approved on April 1, 2026, for long-term weight management in adults with obesity, or with overweight and at least one weight-related condition.

Where it wins

  • Taken with or without food
  • A tablet, with no needle
  • A different GLP-1 drug from tirzepatide

What it costs you

  • One tablet every day
  • Six dose levels, each held at least 30 days before the next
  • Not for anyone with a personal or family history of MTC or MEN 2

A daily pill with no food timing

06

The Wegovy pill

Semaglutide tablet, FDA approved 2025

Dailybrand tablet

The Wegovy pill is semaglutide as a once-daily tablet, FDA approved on December 22, 2025. Its label covers long-term weight management in adults, and lowering the risk of major cardiovascular events in adults with heart disease and obesity or overweight.

Where it wins

  • Brand semaglutide with no needle
  • Maintenance dose of 25 mg once a day
  • Shares a label with the Wegovy injection

What it costs you

  • Taken on an empty stomach each morning with up to 4 ounces of water, then a 30-minute wait before food, drink or other oral medicines
  • Labeled for adults, while the Wegovy injection label starts at age 12
  • Not for anyone with a personal or family history of MTC or MEN 2

Brand semaglutide in tablet form

07

Saxenda

Liraglutide injection, FDA approved 2014

Dailybrand injection

Saxenda is liraglutide 3 mg, a GLP-1 receptor agonist injected once a day. Approved on December 23, 2014, it is the oldest approval on this list, and a generic liraglutide injection with the same weight-management indication is now listed on DailyMed.

Where it wins

  • Approved since 2014, the longest record here
  • A generic with the same indication
  • Label covers obesity from age 12 (over 60 kg) and adults with overweight plus a condition tied to weight

What it costs you

  • An injection every day instead of every week
  • The label says to stop if you have not lost at least 4% of your weight by week 16
  • Not for anyone with a personal or family history of MTC or MEN 2

When a generic GLP-1 matters most

How to choose a Zepbound alternative

The right Zepbound alternative depends on why the brand pen is not working out for you, because cost, coverage, needles and the drug itself each point somewhere else.

Your reasonOptions to raise with a clinician
Cost, or no coverageCompounded tirzepatide in a cash-pay program (not FDA approved), or the brand your plan does cover
You want to stay on tirzepatideCompounded tirzepatide (not FDA approved) or Zepbound vials
You want a different drugWegovy, or compounded semaglutide (not FDA approved)
You want a pillFoundayo or the Wegovy pill
You want an FDA-approved genericGeneric liraglutide, the drug in Saxenda
You take Mounjaro for type 2 diabetesThe clinician who manages your diabetes, before any change

A starting point for the conversation, not a prescription. Harbor offers the two compounded injections, and no pill, brand drug or liraglutide.

If the problem is paying for Zepbound without insurance, coverage is uneven to begin with. NIDDK notes that some, but not all, insurance plans cover medications that treat overweight and obesity. A cash-pay program removes the coverage question, though never the prescription.

Compounded drugs are not FDA approved, and FDA advises getting a prescription and filling it at a state-licensed pharmacy. Whether a compounded drug fits you is the prescribing clinician's call. Why the two routes are priced so differently is explained in tirzepatide brand vs compounded price.

Every drug on this list is ruled out by a personal or family history of medullary thyroid carcinoma or MEN 2. The Zepbound label also advises against using it with any other tirzepatide product or GLP-1 drug, so a move to another option is a switch and never an add-on. The compounded programs are for adults 18 and older and are not available during pregnancy, breastfeeding or while planning a pregnancy. For your own history, message your clinician.

Compounded tirzepatide shots with Harbor

For a reader leaving Mounjaro or Zepbound over cost or coverage, the closest routine is another weekly tirzepatide shot. Harbor compounded tirzepatide, which is not FDA approved, is a once-weekly injection you give yourself at home, in a program that puts medication, clinician care and check-ins in one price. No insurance is required, and HSA and FSA cards are accepted.

The compounded tirzepatide cost in this program starts at $119 a month and stays flat as your dose goes up. Kendra Freeman described the pricing on Trustpilot in August 2026: "Needing to up your dose great no problem costs stay the same."

It is not Mounjaro or Zepbound, and it is not a generic of either. A board-certified physician licensed in your state reviews your intake and decides whether treatment is appropriate before anything ships. If a clinician does not approve treatment, the payment is refunded in full.

Switching from a brand pen starts with three details in your intake: your current medication, your dose and the date of your last injection. In most cases you can continue at your current dose or request an increase rather than restarting titration, and your provider makes the final call. A member who switched, Hope Osborne, wrote on Trustpilot in October 2026 that support "made the whole change feel much less complicated."

Each shipment of the compounded tirzepatide, which is not FDA approved, holds a multi-dose vial, U-100 insulin syringes, alcohol prep pads and a sharps container. The program is also designed to end: when you reach your goal, it moves to a structured, clinician-guided taper and registered-dietitian aftercare. The online quiz takes about 90 seconds, and there is no charge to find out.

This article is for general education and is not medical advice. It is not a substitute for evaluation, diagnosis, or treatment by a licensed clinician. Talk with a qualified clinician about your individual situation.

Harbor is a technology platform. Medical evaluations are conducted by independent, licensed healthcare providers who determine whether treatment is appropriate. Compounded medications are not FDA approved and are not reviewed by the FDA for safety or effectiveness.

Frequently asked questions

There is no generic tirzepatide yet: as of November 2026, Drugs@FDA lists only Mounjaro and Zepbound. The lower-cost routes to ask about are your plan's coverage, since some plans cover weight medication, and a cash-pay Mounjaro alternative such as a compounded tirzepatide program, which is not FDA approved, from $119 a month with no insurance required. Which costs you less depends on your plan and your dose, so compare what each monthly price includes.

Harbor's compounded tirzepatide, which is not FDA approved, starts at $119 a month, and that one price covers the medication, clinician care and check-ins. The price stays flat as your dose goes up, there are no membership fees, and HSA and FSA cards are accepted. Prepaid plans billed every 3, 6 or 12 months are discounted against monthly billing.

It depends on the option. Semaglutide, the drug in Wegovy, has been tested against tirzepatide directly: in SURMOUNT-5, a 72-week trial of 751 adults, mean weight loss was 20.2% on tirzepatide and 13.7% on semaglutide. Foundayo, the Wegovy pill and Saxenda were each tested against placebo, not against Zepbound. Compounded tirzepatide, which is not FDA approved, was not part of any of these trials, so whether it fits you is a licensed clinician's decision, made after reviewing your history.

Sources

  1. Mounjaro (tirzepatide) label, revised August 2026, DailyMed.
  2. Mounjaro NDA 215866 approval history, Drugs@FDA.
  3. Zepbound (tirzepatide) label, revised August 2026, DailyMed.
  4. Zepbound NDA 217806 approval history, Drugs@FDA.
  5. SURMOUNT-5, tirzepatide compared with semaglutide (NCT05822830), ClinicalTrials.gov.
  6. Wegovy (semaglutide) injection and tablets label, DailyMed.
  7. Wegovy injection NDA 215256 approval history, Drugs@FDA.
  8. Wegovy tablets NDA 218316 approval history, Drugs@FDA.
  9. Foundayo (orforglipron) tablets label, DailyMed.
  10. FDA approves Foundayo (orforglipron), April 1, 2026.
  11. Saxenda (liraglutide) label, DailyMed.
  12. Saxenda NDA 206321 approval history, Drugs@FDA.
  13. Liraglutide injection (generic, weight management) label, DailyMed.
  14. FDA's concerns with unapproved GLP-1 drugs used for weight loss.
  15. Prescription medications to treat overweight and obesity, NIDDK.
  16. Tirzepatide injection, MedlinePlus drug information.
  • Tirzepatide

    Contrave is a twice-daily tablet. Tirzepatide is a once-weekly injection. Here is how they compare on trial results, routine, FDA status and cost, and what a licensed clinician checks before prescribing either one.

    By Harbor Health Team

  • Tirzepatide

    Mounjaro and Trulicity are weekly type 2 diabetes shots. SURPASS-CVOT compared them directly for about four years. Here is what it found for A1C, weight and heart events.

    By Harbor Health Team